Page last updated: 2024-08-24

cidofovir anhydrous and Burkitt Lymphoma

cidofovir anhydrous has been researched along with Burkitt Lymphoma in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abdulkarim, B; Bourhis, J; Deutsch, E; Frascogna, V; Joab, I; Klijanienko, J; Sabri, S; Vainchenker, W; Zelenika, D	1
Agbalika, F; Hocqueloux, L; Molina, JM; Oksenhendler, E	1

Other Studies

2 other study(ies) available for cidofovir anhydrous and Burkitt Lymphoma

Article	Year
Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies. Oncogene, 2003, Apr-17, Volume: 22, Issue:15 Topics: Animals; Antiviral Agents; Apoptosis; bcl-2-Associated X Protein; Burkitt Lymphoma; Carcinoma; Caspase 3; Caspase 9; Caspases; Cell Division; Cidofovir; Combined Modality Therapy; Cytosine; Enzyme Activation; Epstein-Barr Virus Infections; Female; Gene Expression Regulation, Viral; Genes, bcl-2; Herpesvirus 4, Human; Humans; Mice; Mice, Nude; Nasopharyngeal Neoplasms; Oncogene Proteins, Viral; Organophosphonates; Organophosphorus Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; Remission Induction; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Virus Infections; Viral Matrix Proteins; Xenograft Model Antitumor Assays	2003
Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS (London, England), 2001, Jan-26, Volume: 15, Issue:2 Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Burkitt Lymphoma; Cidofovir; Cytosine; Herpesvirus 4, Human; Herpesvirus 8, Human; HIV Long-Term Survivors; HIV Protease Inhibitors; Humans; Interferon-alpha; Lymphoma, B-Cell; Male; Organophosphonates; Organophosphorus Compounds; Pleural Effusion; Sarcoma, Kaposi; Time Factors	2001

Article

Year

Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.

Oncogene, 2003, Apr-17, Volume: 22, Issue:15

Topics: Animals; Antiviral Agents; Apoptosis; bcl-2-Associated X Protein; Burkitt Lymphoma; Carcinoma; Caspase 3; Caspase 9; Caspases; Cell Division; Cidofovir; Combined Modality Therapy; Cytosine; Enzyme Activation; Epstein-Barr Virus Infections; Female; Gene Expression Regulation, Viral; Genes, bcl-2; Herpesvirus 4, Human; Humans; Mice; Mice, Nude; Nasopharyngeal Neoplasms; Oncogene Proteins, Viral; Organophosphonates; Organophosphorus Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; Remission Induction; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Virus Infections; Viral Matrix Proteins; Xenograft Model Antitumor Assays

2003

Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy.

AIDS (London, England), 2001, Jan-26, Volume: 15, Issue:2

Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Burkitt Lymphoma; Cidofovir; Cytosine; Herpesvirus 4, Human; Herpesvirus 8, Human; HIV Long-Term Survivors; HIV Protease Inhibitors; Humans; Interferon-alpha; Lymphoma, B-Cell; Male; Organophosphonates; Organophosphorus Compounds; Pleural Effusion; Sarcoma, Kaposi; Time Factors

2001